MedTrace Logo

Diclofenac Potassium on IANB Efficacy in Symptomatic Irreversible Pulpitis

NCT03163420 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-05-23

No results posted yet for this study

Summary

The aim of this clinical trial is to evaluate the effect of pre-operative administration of diclofenac potassium on the efficacy of inferior alveolar nerve block on using 2% mepivacaine anaesthetic agent in patients with symptomatic irreversible pulpitis.

Conditions

  • Irreversible Pulpitis

Interventions

DRUG

Diclofenac potassium

Diclofenac potassium 50 mg granules for oral solution

OTHER

Placebo

Fructose

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Khaled M Ezzat, Professor · Faculty of Oral and Dental medicine, Cairo University

  • Suzan AW Amin, PhD · Faculty of Oral and Dental medicine, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163420 on ClinicalTrials.gov